Kindred Biosciences (NASDAQ:KIN), (ELAN) - Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
SPAC
Email
Thank You
Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com Start Investing
Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit
News provided by
Share this article
Share this article
SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25.
Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones.
An archived version of the above webcast will be available for 30 days on the KindredBio website.
Kindred Biosciences Announces Two New Appointments to Board of Directors
News provided by
Share this article
Share this article
SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its Board of Directors, effective February 5, 2021. We are very pleased to welcome Lyndon and Nanxi to our Board, said Chief Executive Officer, Richard Chin, M.D. With extensive investing, operating, and business development experience, Lyndon will bring valuable additional perspectives to KindredBio. Nanxi is a seasoned entrepreneur recognized by Forbes and Fortune magazines, who brings management and public board experience to KindredBio. We look forward to working with them as we advance our in
Share this article
Share this article
SAN FRANCISCO, Dec. 22, 2020 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal efficacy study for tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin (IL)-31 for the treatment of atopic dermatitis in dogs.
Atopic dermatitis is the most common reason owners take their dog to the veterinarian, and is estimated to affect 10 - 15% of dogs worldwide
1. The current market size is close to $900 million annually and growing. Commencement of the tirnovetmab pivotal study marks an important milestone for KindredBio, said Chief Executive Officer, Richard Chin, M.D. The market for canine atopic dermatitis, allergic dermatitis, and other pruritic diseases already rivals that of many successful human drugs, and continues to experience strong growth. Our market research